3 Houston innovators to know this week

who's who

This week's Houston innovators to know include Nicolaus Radford of Houston Mechatronics Inc. and Sharita M. Humphry and Enrique Castro of BH Ventures. Photos courtesy

Editor's note: This week's roundup of innovators to know in Houston include three self-starting founders — a robotics expert who's job sounds more futuristic that realistic and a duo looking to bridge the gap between Black and Hispanic entrepreneurs while cultivating their business growth.

Nicolaus Radford, CEO, CTO, and co-founder of Houston Mechatronics Inc.

Nicolaus Radford joins the Houston Innovators Podcast to discuss his plans to take his cloud robotics company global. Photo courtesy of HMI

Discussing Nicolaus Radford's career and his current work with his company, Houston Mechatronics Inc., feels like something out of a science fiction movie. But it's real life. HMI is building a fleet of underwater robots, and, before he founded his company in 2014, he worked on humanoid robots for NASA.

Now, there's a growing market need for the type of robots HMI is working on, and he share on the Houston Innovators Podcast that there's a huge international opportunity for him.

"We're absolutely going to be a global company," Radford says, explaining that new clients in these areas are what's calling for the new offices. "The next 12 months of this company are going to be extremely vibrant and dynamic." Read more.

Enrique Castro and Sharita M. Humphry of BH Ventures

Enrique Castro and Sharita M. Humphrey met at an alumni event at UH and decided to work together on an inclusive accelerator program. Courtesy photos

Black and Hispanics tend to fall low on the lists of personal finance and business success, and usually the two communities don't do business together. That's what BH Ventures, a business accelerator program founded by Sharita M. Humphrey and Enrique Castro, is looking to change.

"Enrique and I know that there can sometimes be a barrier between Black and Hispanics doing business together," says Humphrey. "This is why I wanted, as an African American woman, and him, being a Hispanic male, to be able to show that we should be doing business together — especially in the city of Houston."

Humphrey and Castro met at an alumni event for the University of Houston's SURE program, which creates educational programming for entrepreneurs from under-resourced communities. The duo thought that they could create a program that built upon UH's. In February, after building out the curriculum, BH Ventures ran a successful pilot program in collaboration with UH. Read more.

BH Ventures is seeking Black and Hispanic entrepreneurs for its inaugural cohort. Photo via Getty Images

New startup accelerator emerges in Houston to promote collaboration between Black and Hispanic communities

teamwork

Two local business leaders have teamed up to create a Houston-based accelerator focused on Black and Hispanic entrepreneurs.

BH Ventures has applications open for its inaugural cohort until August 21, and co-founders Sharita M. Humphrey and Enrique Castro are looking for founders who have hit the revenue-generating phase with their business but are looking for mentors and support as they grow.

"Enrique and I know that there can sometimes be a barrier between Black and Hispanics doing business together," says Humphrey. "This is why I wanted, as an African American woman, and him, being a Hispanic male, to be able to show that we should be doing business together — especially in the city of Houston."

Humphrey and Castro met at an alumni event for the University of Houston's SURE program, which creates educational programming for entrepreneurs from under-resourced communities. The duo thought that they could create a program that built upon UH's. In February, after building out the curriculum, BH Ventures ran a successful pilot program in collaboration with UH.

Enrique Castro and Sharita M. Humphrey met at an alumni event at UH and decided to work together on an inclusive accelerator program. Courtesy photos

The seven-month program will launch virtually at the beginning of September and will work with 15 entrepreneurs across the country. Additionally, The Cannon is a partner and a resource for the program.

As of now, the program has over 20 mentors and speakers lined up, and sessions will occur virtually every other Saturday and will be a mix of presentations and Q&As with an emphasis on fostering networking connections.

"Sometimes for a Black or Hispanic entrepreneur, just being able to have that conversation or be able to ask (a mentor) certain questions and get feedback about their particular business — it's better than money," Humphrey says. "The right relationships can open up doors that money can't."

After the programming, Humphrey says BH Ventures will continue to follow each company from the cohort for 90 days in a sort of incubation period to make sure they have support after the accelerator.

"It's a lot to get the information — but how do you execute it? We're going to still follow their path," Humphrey says.

While Houston has been renown for being the most diverse city in the country, Humphrey says she's seen a shift in leadership diversity across the greater Houston area. This has motivated her to do everything she can to promote inclusion and business growth across demographics.

"(Blacks and Hispanics are) not doing as much business together as we could," Humphrey says. "And that makes no sense when we are normally at the bottom of things when it comes to finances — personal, savings, credit, wealth, business. I think that this is something that's going to be amazing for the city."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.

View All Listings